RBM15 single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
RBM15
Disease:
Megakaryoblastic Acute Myeloid Leukemia With T(1;22)(P13;Q13) and Acute Megakaryocytic Leukemia, breast invasive ductal carcinoma, ovarian serous adenocarcinoma, lung adenocarcinoma, and sebaceous carcinoma
Next generation sequencing of gene panel. Members of the SPEN (Split-end) family of proteins, including RBM15, have repressor function in several signaling pathways and may bind to RNA through interaction with spliceosome components
Specimen Requirements
Collection:
3 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens for RNA gene fusion detection
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81479
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
